» Articles » PMID: 9679876

Treatment of Male Urethral Strictures: is Repeated Dilation or Internal Urethrotomy Useful?

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1998 Jul 29
PMID 9679876
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We evaluate the efficacy of repeated dilation or urethrotomy as treatment of male urethral strictures.

Materials And Methods: Between January 1991 and January 1994, 210 men with proved urethral strictures were prospectively randomized to undergo filiform dilation (106) or internal urethrotomy (104). Followup was scheduled at 3, 6, 9, 12, 24, 36 and 48 months. Dilation or internal urethrotomy was repeated at the first and second stricture recurrence. The Kaplan-Meier method was used to estimate survivor function for the treatment methods (survival time being the time to first stricture recurrence) and the log rank test was used to compare the efficacy of different treatments.

Results: Followup (mean 24 months, range 2 to 63) was available in 163 patients (78%). After a single dilation or urethrotomy not followed by re-stricturing at 3 months, the estimated stricture-free rate was 55 to 60% at 24 months and 50 to 60% at 48 months. After a second dilation or urethrotomy for stricture recurrence at 3 months the stricture-free rate was 30 to 50% at 24 months and 0 to 40% at 48 months. After a third dilation or urethrotomy for stricture recurrence at 3 and 6 months the stricture-free rate at 24 months was 0 (p <0.0001).

Conclusions: Dilation and internal urethrotomy are useful in a select group (approximately 70% of all patients) who are stricture-free at 3 months, and of whom 50 to 60% will remain stricture-free up to 48 months. A second dilation or urethrotomy for early stricture recurrence (at 3 months) is of limited value in the short term (24 months) but of no value in the long term (48 months), whereas a third repeated dilation or urethrotomy is of no value.

Citing Articles

Evaluating the impact of a urethral reconstruction fellowship on urethral stricture disease management at a regional hospital.

Gurbani C, Brodie B, Eardley I, Lau W Transl Androl Urol. 2025; 14(1):60-69.

PMID: 39974808 PMC: 11833525. DOI: 10.21037/tau-24-550.


Urethroplasty- a single centre single surgeon experience.

McNicholas D, Taylor A, Baird A Ir J Med Sci. 2024; 193(6):3059-3064.

PMID: 39225738 PMC: 11666646. DOI: 10.1007/s11845-024-03798-z.


Optilume drug-coated balloon for anterior urethral stricture: 2-year results of the ROBUST III trial.

VanDyke M, Morey A, Coutinho K, Robertson K, DAnna R, Chevli K BJUI Compass. 2024; 5(3):366-373.

PMID: 38481667 PMC: 10927926. DOI: 10.1002/bco2.312.


Outcomes of HUD Versus CIC in Patients With Urethral Strictures.

Hosseini J, Mirjalili A, Sharifian R, Abouei S, Tajamolian R, Samadaee Gelehkolaee K Am J Mens Health. 2023; 17(5):15579883231202714.

PMID: 37811639 PMC: 10563477. DOI: 10.1177/15579883231202714.


Economic evaluation of Optilume, a drug-coated balloon for recurrent anterior male urethral stricture.

Kelly L, Shore J, Wright J, Patrick C, Holmes H BJUI Compass. 2023; 4(4):430-436.

PMID: 37334026 PMC: 10268567. DOI: 10.1002/bco2.241.